Pace(R) Life Sciences to Expand Large Molecule Development, Manufacturing, and Analytical Testing Capacity in 2025
MINNEAPOLIS, MN / ACCESSWIRE / January 10, 2025 / Pace® Life Sciences, LLC, a U.S.-based contract research, development, and ...
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
ORLADEYO net revenue expected to be between $515-$535 million in 2025——Total revenue (including RAPIVAB®) expected to be between $540-$560 ...
FiercePharma2d
CDMO National Resilience plots 120 layoffs at former bluebird bio facility in Research Triangle Park
Following a fresh round of job cuts in December, CDMO National Resilience is carrying its downsizing efforts into 2025. | ...
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare ...